Solventum (NYSE:SOLV) vs. NeurAxis (NASDAQ:NRXS) Head to Head Review

NeurAxis (NASDAQ:NRXS) and Solventum (NYSE:SOLV) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Institutional & Insider Ownership

11.8% of NeurAxis shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Comparatively, 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares NeurAxis and Solventum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Solventum	17.26%	25.09%	8.78%

Valuation & Earnings

This table compares NeurAxis and Solventum”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32 million	16.13	-$14.63 million	($0.78)	-8.76
Solventum	$8.32 billion	1.76	$1.56 billion	$8.18	10.50

Solventum has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for NeurAxis and Solventum, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	1	1	0	2.50
Solventum	1	3	8	0	2.58

NeurAxis presently has a consensus target price of $13.00, suggesting a potential upside of 90.34%. Solventum has a consensus target price of $92.80, suggesting a potential upside of 8.07%. Given NeurAxis’ higher probable upside, equities research analysts plainly believe NeurAxis is more favorable than Solventum.

Risk & Volatility

NeurAxis has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Solventum has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.

Summary

Solventum beats NeurAxis on 9 of the 14 factors compared between the two stocks.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.